Institutional investors purchased a net $1.5 million shares of HALO during the quarter ended September 2017. This may signal that the smart money is gaining interest in this company as the 73.67% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BLACKROCK FUND ADVISORS Bought 648.3 Thousand shares of Halozyme Therapeutics Inc
RUBRIC CAPITAL MANAGEMENT LP Bought 483.0 Thousand shares of Halozyme Therapeutics Inc